Category: imidazoles-derivatives

Doan, Sengul Dilem; Ongun, Melike published an article in 2022, the title of the article was Copper catalyzed C-N bond formation and synthesis of imidazopyridinone derivatives.Reference of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one And the article contains the following content:

A series of novel imidazopyridinone derivatives were synthesized via copper-mediated C-N bond-forming reaction. This reaction takes place under mild conditions with high efficiency, step economy, and tolerance for a wide range of functional groups. All synthesized new compounds were analyzed by 1H NMR, 13C NMR and mass spectrometry. The experimental process involved the reaction of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one(cas: 41010-50-8).Reference of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one

The Article related to bromopyridylphenylurea copper iodide catalyst microwave intramol cyclization, imidazopyridinone preparation, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Reference of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On January 31, 2008, Khomenko, T. M.; Volcho, K. P.; Komarova, N. I.; Salakhutdinov, N. F. published an article.Reference of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole The title of the article was An efficient procedure for the synthesis of Esomeprazole using a titanium complex with two chiral ligands. And the article contained the following:

A procedure has been proposed for the selective preparation of Esomeprazole [(S)-I] via asym. oxidation of the corresponding prochiral sulfide in the presence of a catalytic complex derived from titanium(IV) isopropoxide and two different chiral ligands, di-Et D-tartrate and (R)-N,N-dimethyl-1-phenylethanamine. The experimental process involved the reaction of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole(cas: 73590-85-9).Reference of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole

The Article related to asym preparation esomeprazole, titanium complex tartrate phenylethanamine asym preparation esomeprazole, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Reference of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On September 16, 2021, Akaboshi, Kazumasa; Sumikawa, Eiken; Furuta, Sadayoshi; Imazu, Takuya; Fukushima, Keiichiro; Furutaka, Ryota published a patent.Name: 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid The title of the patent was Preparation of heteroaromatic amide derivative for inhibiting Nav1.7. And the patent contained the following:

The present invention relates to a compound I [X-Y = N-C or C-N; Y1-Y4 = independently single bond, -CH2-, -CH2CH2-, etc.; Z1 = single bond, -O-, -S-, etc.; ring A = monocyclic aromatic ring or bicyclic aromatic ring; R1a, R1b = independently H, halo, hydroxy, etc.; R2 = H, halo, hydroxy, etc.; R3a, R3b, R3c = independently H, halo, cyano, etc.; combination of R5a, R5b, R5c, R6a, R6b and n is selected from (1), (2), (3), etc.; (1) R5b and R5c combine to form a single bond, -CH2-, -OCH2-, etc., R5a is H, alkyl, haloalkyl, etc., R6a and R6b each is H, halo, hydroxy, etc., and n is 1 or 2 (2) R5a and R6a combine to form -CH2-, -CH2CH2-, -CH2CH2O-, etc., R5b is H, alkyl or haloalkyl, R5c and R6b each is H, halo, hydroxy, etc. (or R5c and R6b may combine to form -(CH2)p-, -O(CH2)p-, -(CH2)pO-, etc. (p = 0-3)), and n is 1 (3) R5a is H, alkyl, haloalkyl, etc., R5b is H or alkyl, R5c is H, alkyl or halo, R6a and R6b each is H, halo, alkyl, etc. (or R6a and R6b, together with the carbon atom to which they are attached, may combine to form a monocyclic ring) and n is 1 or 2; or a salt thereof]. For example, compound II was prepared via cyclization of 5-(trifluoromethyl)pyridin-2-amine with Et bromopyruvate, hydrogenation, hydrolysis and HATU-mediated amidation with 6-fluorochroman-3-amine·HCl. Compound I shows selective inhibition of potential-dependent sodium channel Nav1.7 over Nav1.5, and is useful for the treatment of pain and various Nav1.7-related disease including pruritus and an autonomic nerve-related disease. The experimental process involved the reaction of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid(cas: 1774893-22-9).Name: 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid

The Article related to heteroaromatic amide preparation voltage gated sodium channel blocker, analgesic heteroaromatic amide, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Name: 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On March 19, 2020, Akahoshi, Issei; Sumikawa, Yoshitake; Furuta, Sadayoshi; Fukushima, Keiichiro; Imazu, Takuya; Kotaka, Ryota published a patent.Recommanded Product: 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid The title of the patent was Preparation of heteroaromatic amide derivative for inhibiting Nav1.7. And the patent contained the following:

The present invention relates to a compound I [X-Y = N-C or C-N; Y1-Y4 = independently single bond, -CH2-, -CH2CH2-, etc.; Z1 = single bond, -O-, -S-, etc.; ring A = monocyclic aromatic ring or bicyclic aromatic ring; R1a, R1b = independently H, halo, hydroxy, etc.; R2 = H, halo, hydroxy, etc.; R3a, R3b, R3c = independently H, halo, cyano, etc.; combination of R5a, R5b, R5c, R6a, R6b and n is selected from (1), (2), (3), etc.; (1) R5b and R5c combine to form a single bond, -CH2-, -OCH2-, etc., R5a is H, alkyl, haloalkyl, etc., R6a and R6b each is H, halo, hydroxy, etc., and n is 1 or 2 (2) R5a and R6a combine to form -CH2-, -CH2CH2-, -CH2CH2O-, etc., R5b is H, alkyl or haloalkyl, R5c and R6b each is H, halo, hydroxy, etc. (or R5c and R6b may combine to form -(CH2)p-, -O(CH2)p-, -(CH2)pO-, etc. (p = 0-3)), and n is 1 (3) R5a is H, alkyl, haloalkyl, etc., R5b is H or alkyl, R5c is H, alkyl or halo, R6a and R6b each is H, halo, alkyl, etc. (or R6a and R6b, together with the carbon atom to which they are attached, may combine to form a monocyclic ring) and n is 1 or 2; or a salt thereof]. For example, compound II was prepared via cyclization of 5-(trifluoromethyl)pyridin-2-amine with Et bromopyruvate, hydrogenation, hydrolysis and HATU-mediated amidation with 6-fluorochroman-3-amine·HCl. Compound I shows selective inhibition of Nav1.7 over Nav1.5, and is useful for the treatment of pain and various Nav1.7-related disease. The experimental process involved the reaction of 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid(cas: 1774893-22-9).Recommanded Product: 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid

The Article related to heteroaromatic amide preparation voltage gated sodium channel blocker, analgesic heteroaromatic amide, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Recommanded Product: 6-(Trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Gupta, Rajender P.; Larroquette, Cynthia A.; Agrawal, Krishna C. published an article in 1982, the title of the article was Potential radiosensitizing agents. 5. 2-Substituted benzimidazole derivatives.Recommanded Product: 5709-67-1 And the article contains the following content:

Benzimidazoles I [R = CH2CH(OH)CH2OMe, CH2CO2Et; R1 = CONH2, Ac, CF3, CN, SO2Me, NO2; R2, R3 = H, NO2] were prepared, e.g., by alkylation of I (R = H) with 1,2-epoxy-3-methoxypropane in the presence of K2CO3. Reaction of I (R1 = NO2, SO2Me) with the epoxide also yielded a benzimidazo[2,1-b]oxazole derivative I (R1 = NO2) showed the highest radiosensitizing activity against Chinese hamster cells (V-79) in culture. The experimental process involved the reaction of 2-Nitro-1H-benzo[d]imidazole(cas: 5709-67-1).Recommanded Product: 5709-67-1

The Article related to benzimidazole nitro preparation radiosensitizer, radiosensitizer nitrobenzimidazole derivative, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Recommanded Product: 5709-67-1

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On June 30, 2021, Zhao, Peng; Ren, Shi-Miao; Liu, Feng; Zheng, Yu-Cong; Xu, Na; Pan, Jiang; Yu, Hui-Lei; Xu, Jian-He published an article.Related Products of 73590-85-9 The title of the article was Protein engineering of thioether monooxygenase to improve its thermostability for enzymatic synthesis of chiral sulfoxide. And the article contained the following:

Esomeprazole, the S-enantiomer of omeprazole, is the best-selling proton pump inhibitor. In our previous work, a mutant of cyclohexanone monooxygenase from the Acinetobacter calcoaceticus (named AcCHMO-M6) was successfully obtained through protein engineering which could catalyze the oxidation of omeprazole sulfide. However, its practical application is still hindered by the poor thermostability, especially in the up-scaled reaction process. In this work, site mutagenesis based on consensus anal. and directed evolution were used to engineer this enzyme in order to improve the stability of AcCHMO-M6. The half-lives of the resultant mutants AcCHMO-M9 (F29L/R444E) and AcCHMO-M10 (F29L/R444E/A145S/G430T) at 40°C were increased from 2.2 h to 8.5 h and 5.9 h resp., while the corresponding Tm values were increased by 7°C and 5.3°C in comparison to AcCHMO-M6. The specific activity of AcCHMO-M9 was comparable to that of AcCHMO-M6, and the specific activity of AcCHMO-M10 was about 4-fold that of AcCHMO-M6. The AcCHMO-M10 catalyzed sulfide oxidation reaction reached 100% conversion after 16 h at 30°C, in contrast to 39.4% conversion in the case of AcCHMO-M6. These results show that the potential of this thioether monooxygenase can be significantly improved by protein engineering. The experimental process involved the reaction of 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole(cas: 73590-85-9).Related Products of 73590-85-9

The Article related to acinetobacter cyclohexanone monooxygenase protein engineering thermostability chiral sulfoxide, Fermentation and Bioindustrial Chemistry: Industrial Chemicals and other aspects.Related Products of 73590-85-9

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On January 12, 1978, Staehle, Helmut; Koeppe, Herbert; Kummer, Werner; Hoefke, Wolfgang published a patent.Product Details of 65896-14-2 The title of the patent was 2-Bromo-6-fluoro-N-2-imidazolidinylideneaniline. And the patent contained the following:

The title compound (I) and its pharmaceutically acceptable salts were prepared by the cyclization of 2,6-FBrC6H3NHC(SR):NH.HX (II; R = alkyl, X = halogen) with H2NCH2CH2NH2. Thus, II (R = Me, X = iodo) was refluxed with H2NCH2CH2NH2 in BuOH and the mixture treated with HCl to give 56.3% I HCl, which has antihypertensive activity comparable to that of clonidine, with fewer side effects, e.g., inhibition of gastric juice secretion. The experimental process involved the reaction of N-(2-Bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride(cas: 65896-14-2).Product Details of 65896-14-2

The Article related to antihypertensive phenyliminoimidazolidine, phenyliminoimidazolidine, imidazolidine phenylimino, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Product Details of 65896-14-2

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On October 31, 1983, Kovac, T.; Oklobdzija, M.; Comisso, G.; Decorte, E.; Fajdiga, T.; Moimas, F.; Angeli, C.; Zonno, F.; Toso, R.; Sunjic, V. published an article.Safety of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one The title of the article was New synthesis of 11-acyl-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones and related studies. And the article contained the following:

11-Acyl-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones I (R = 4-methylpiperazino, imidazolo, 2-methylimidazolo) were prepared via N-α-chloroacetylation and aminolysis. Other attempts at cyclization to form I are also reported. The experimental process involved the reaction of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one(cas: 41010-50-8).Safety of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one

The Article related to aminoacetylpyridobenzodiazepinone, pyridobenzodiazepinone aminoacetyl, benzodiazepinone pyrido, Heterocyclic Compounds (More Than One Hetero Atom): Diazepines and other aspects.Safety of 3-Phenyl-1H-imidazo[4,5-b]pyridin-2(3H)-one

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On September 28, 1992, Li, M. J.; Li, S. Z.; Zhuang, X. L.; Chen, A.; Zhang, H. Q.; Pang, X. C.; Hu, B. published an article.Application of 5709-67-1 The title of the article was Synthesis and radiosensitizing activity of benzimidazoles. And the article contained the following:

Reaction of 2-nitrobenzimidazole with Et chloroformate yielded Et (2-nitrobenzimidazol-1-yl)formate or Et (2-hydroxybenzimidazol-1-yl)formate, depending upon the solvents used. Reaction of 2-nitrobenzimidazole with 1,2-epoxy-3-chloropropane gave a cyclized compound I. In an attempt to increase hydrophilicity, 1-substituted 2-(3′-pyridyl)-5-nitrobenzimidazoles were prepared by reaction of 2-(3′-pyridyl)-5(6)-nitrobenzimidazole with alkyl epoxides or Et chloroacetate. Some of the compounds synthesized were tested for radiosensitizing activity in Ehrlich ascites carcinoma-bearing mice. Preliminary results showed that some compounds have radiosensitizing activity. The radiosensitizing enhancement ratio (SER) of compounds I and II (R = H, Me) were 1.50, 1.52 and 1.65 resp. The experimental process involved the reaction of 2-Nitro-1H-benzo[d]imidazole(cas: 5709-67-1).Application of 5709-67-1

The Article related to benzimidazole preparation radiosensitizer, nitrobenzimidazole preparation radiosensitizer, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Application of 5709-67-1

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

On December 13, 2019, Aspnes, Gary Erik; Bagley, Scott W.; Curto, John M.; Edmonds, David James; Flanagan, Mark E.; Futatsugi, Kentaro; Griffith, David A.; Huard, Kim; Lian, Yajing; Limberakis, Chris; Londregan, Allyn T.; Mathiowetz, Alan M.; Piotrowski, David W.; Riggeri, Roger B. published a patent.Category: imidazoles-derivatives The title of the patent was Preparation of 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists for the treatment of diseases. And the patent contained the following:

Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof. The example compound (I) was prepared by multistep synthesis (procedure given). The compounds of the invention were evaluated for their biol. activity (data given). The compounds of the invention can be used in treatment of diseases, such as NASH, diabetes, obesity and like. The experimental process involved the reaction of (1-Ethyl-1H-imidazol-5-yl)methanamine dihydrochloride(cas: 1255717-13-5).Category: imidazoles-derivatives

The Article related to benzimidazole carboxylic acid salt preparation glp1r agonist disease treatment, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Category: imidazoles-derivatives

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem